Metronidazole citrate ester as the new prodrug of metronidazole

Pharmacokinetics of metronidazole as determined by bioassay.

The pharmacokinetics of metronidazole, a drug effective in vitro against most anaerobic bacteria and promising in treating anaerobic infections, are described. Serum and urine levels after single and multiple doses in 10 adult male volunteers were measured by an agar well diffusion bioassay using clostridial species as the test organisms under anaerobic conditions. Peak serum levels averaged 11...

Metronidazole neuropathy.

Two patients are described who developed sensory neuropathy after the ingestion of 30.6 and 114 g metronidazole respectively. The drug, widely used in gastroenterological and gynaecological practice, has not hitherto been considered neurotoxic. The implications are stressed in relation to the differential diagnosis of patients with gastroenterological disorders who develop peripheral neuropathy.

Clinical pharmacokinetics of metronidazole.

Metronidazole and pregnancy.

Since metronidazole is so widely used, it is important to know whether there is any risk from giving the drug during pregnancy. Many drugs are now withheld during early pregnancy, unless their administration is considered essential. There are, however, patients to whom drugs are given before the existence of pregnancy is recognized. In such cases there may be risks of foetal malformations. Apar...

Bioavailability File: Metronidazole

Bioavailability File: Metronidazole Summary Metronidazole is an antimicrobial nitroimidazole derivative, which was originally introduced to treat Trichomonas vaginalis but nowadays is used for the treatment of anaerobic and protozoal infections. Metronidazole is bactericidal through toxic metabolites, which cause deoxyribonucleic acid (DNA) strand breakage. It has a bioavailability of more than...